Herring WL, Gould IG, Wittrup-Jensen V, Ertle J, Kuti E, Wolowacz S. Evaluation of emerging NASH therapies: the impact of treatment efficacy profiles on long-term health outcomes. J Comp Eff Res. 2022 Dec 1;11(18):1349-63. doi: 10.2217/cer-2021-0194
Joshi K, Muser E, Xu Y, Schwab P, Datar M, Suehs B. Adherence and economic impact of paliperidone palmitate versus oral atypical antipsychotics in a Medicare population. J Comp Eff Res. 2018 Aug;7(8):723-35. doi: 10.2217/cer-2018-0003
Meyers J, Gajria K, Candrilli SD, Fridman M, Sikirica V. The impact of adjunctive guanfacine extended release on stimulant adherence in children/adolescents with attention-deficit/hyperactivity disorder. J Comp Eff Res. 2017 Mar;6(2):109-25. doi: 10.2217/cer-2016-0039
Nagar SP, Patel A, Bali V, Aparasu RR. Prevalence and predictors of pediatric depression in the United States. Int J Pharm Sci Nanotech. 2014 Sep;7(3):91-7.
Nagar SP, Mhatre S, Hatfeild MD, Aparasu RR. Patterns and predictors of antipsychotic usage among U.S. adults: a national co-morbidity survey replication study. Int J Pharm Sci Nanotech. 2014 Apr;7(2):52-68.